» Articles » PMID: 2874668

[Acute Effect of the Cardioselective Beta-1-partial Agonist, Corwin, on Ventricular Function and Myocardial Oxygen Consumption in Patients with Dilated Cardiomyopathy]

Overview
Journal Z Kardiol
Date 1986 May 1
PMID 2874668
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The effects on left ventricular function and myocardial metabolism of Corwin (ICI 118,587), a selective beta-1 partial agonist, were evaluated in 12 patients with dilated cardiomyopathy. All patients were in sinus rhythm at the time of cardiac catheterization. Immediately before and 20 minutes after intravenous administration of 0.2 mg/kg Corwin over 2 minutes, high-fidelity left ventricular pressures and thermodilution coronary sinus blood flow were recorded along with ventriculograms in the 30 degrees right anterior oblique projection. In 11 patients, Corwin resulted in no change in heart rate, a fall in left ventricular end-diastolic pressure, a rise in left ventricular systolic pressure and an increase in cardiac index. There was a rise in both peak positive and peak negative dP/dt. End-diastolic and end-systolic volume indices fell, and ejection fraction rose. There was an increase in coronary sinus blood flow and a small rise in myocardial oxygen consumption. In contrast to these results in the group as a whole, in one patient Corwin produced depression of both systolic and diastolic left ventricular function. We conclude that, in many patients with dilated cardiomyopathy, Corwin produces an improvement in systolic and diastolic left ventricular function while at the same time only slightly increasing myocardial oxygen demand. In some patients, however, Corwin may result in a significant worsening of left ventricular performance due to its antagonistic effects.

Citing Articles

Renal effects of xamoterol in patients with moderate heart failure.

Botker H, Jensen H, Krusell L, Sorensen E Cardiovasc Drugs Ther. 1993; 7(1):111-6.

PMID: 8485065 DOI: 10.1007/BF00878318.


Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

FURLONG R, Brogden R Drugs. 1988; 36(4):455-74.

PMID: 2906865 DOI: 10.2165/00003495-198836040-00004.


Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.

Virk S, Davies M Br J Clin Pharmacol. 1989; 28 Suppl 1:15S-22S.

PMID: 2572250 PMC: 1379872.